Effects of Hormone Therapy on Cognition and Mood in Recently Postmenopausal Women: Findings from the Randomized, Controlled KEEPS–Cognitive and Affective Study
Open accessThe DOI matches its Crossref record; 74 of the 74 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Menopausal hormone therapy (MHT) reportedly increases the risk of cognitive decline in women over age 65 y. It is unknown whether similar risks exist for recently postmenopausal women, and whether MHT affects mood in younger women. The ancillary Cognitive and Affective Study (KEEPS-Cog) of the Kronos Early Estrogen Prevention Study (KEEPS) examined the effects of up to 4 y of MHT on cognition and mood in recently postmenopausal women. METHODS AND FINDINGS: KEEPS, a randomized, double-blinded, placebo-controlled clinical trial, was conducted at nine US academic centers. Of the 727 women enrolled in KEEPS, 693 (95.3%) participated in the ancillary KEEPS-Cog, with 220 women randomized to receive 4 y of 0.45 mg/d oral conjugated equine estrogens (o-CEE) plus 200 mg/d micronized progesterone (m-P) for the first 12 d of each month, 211 women randomized to receive 50 μg/d transdermal estradiol (t-E2) plus 200 mg/d m-P for the first 12 d of each month, and 262 women randomized to receive placebo pills and patches. Primary outcomes included the Modified Mini-Mental State examination; four cognitive factors: verbal learning/memory, auditory attention/working memory, visual attention/executive function, and speeded language/mental flexibility; and a mood measure, the Profile of Mood States (POMS). MHT effects were analyzed using linear mixed-effects (LME) models, which make full use of all available data from each participant, including those with missing data. Data from those with and without full data were compared to assess for potential biases resulting from missing observations. For statistically significant results, we calculated effect sizes (ESs) to evaluate the magnitude of changes. On average, participants were 52.6 y old, and 1.4 y past their last menstrual period. By month 48, 169 (24.4%) and 158 (22.8%) of the 693 women who consented for ancillary KEEPS-Cog were lost to follow-up for cognitive assessment (3MS and cognitive factors) and mood evaluations (POMS), respectively. However, because LME models make full use all available data, including data from women with missing data, 95.5% of participants were included in the final analysis (n = 662 in cognitive analyses, and n = 661 in mood analyses). To be included in analyses, women must have provided baseline data, and data from at least one post-baseline visit. The mean length of follow-up was 2.85 y (standard deviation [SD] = 0.49) for cognitive outcomes and 2.76 (SD = 0.57) for mood outcomes. No treatment-related benefits were found on cognitive outcomes. For mood, model estimates indicated that women treated with o-CEE showed improvements in depression and anxiety symptoms over the 48 mo of treatment, compared to women on placebo. The model estimate for the depression subscale was -5.36 × 10(-2) (95% CI, -8.27 × 10(-2) to -2.44 × 10(-2); ES = 0.49, p < 0.001) and for the anxiety subscale was -3.01 × 10(-2) (95% CI, -5.09 × 10(-2) to -9.34 × 10(-3); ES = 0.26, p < 0.001). Mood outcomes for women randomized to t-E2 were similar to those for women on placebo. Importantly, the KEEPS-Cog results cannot be extrapolated to treatment longer than 4 y. CONCLUSIONS: The KEEPS-Cog findings suggest that for recently postmenopausal women, MHT did not alter cognition as hypothesized. However, beneficial mood effects with small to medium ESs were noted with 4 y of o-CEE, but not with 4 y of t-E2. The generalizability of these findings is limited to recently postmenopausal women with low cardiovascular risk profiles. TRIAL REGISTRATION: ClinicalTrials.gov NCT00154180 and NCT00623311.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Folstein, M. F., Folstein, S. E., & McHugh, P. R. (1975) · Journal of Psychiatric Research · doi:10.1016/0022-3956(75)90026-6 · Cited by 88,282
Statistical power analysis for the behavioral sciences
(1990) · Computers, Environment and Urban Systems · doi:10.1016/0198-9715(90)90050-4 · Cited by 65,269
The CES-D Scale: A Self-Report Depression Scale for Research in the General Population
Radloff, L. S. (1977) · Applied Psychological Measurement · doi:10.1177/014662167700100306 · Cited by 53,267
Association of apolipoprotein E allele ϵ4 with late‐onset familial and sporadic Alzheimer's disease
Saunders, A. M., Strittmatter, W. J., Schmechel, D., St. George-Hyslop, P. H., Pericak-Vance, M. A., Joo, S. H., Rosi, B. L., Gusella, J. F., Crapper-MacLachlan, D. R., Alberts, M. J., et al. (1993) · Neurology · doi:10.1212/wnl.43.8.1467 · Cited by 3,786
Wechsler Adult Intelligence Scale-III
Ryan, J. J., & Lopez, S. J. (2001) · Understanding Psychological Assessment · doi:10.1007/978-1-4615-1185-4_2 · Cited by 3,731
Dworkin, R. H., Turk, D. C., Wyrwich, K. W., Beaton, D., Cleeland, C. S., Farrar, J. T., Haythornthwaite, J. A., Jensen, M. P., Kerns, R. D., Ader, D. N., et al. (2008) · The Journal of Pain · doi:10.1016/j.jpain.2007.09.005 · Cited by 3,471 · cited 1×
“Standards for interpreting the clinical significance of POMS score changes were established for clinical trials examining pain control [46].”
Method(1987) · PubMed · Cited by 2,657
Shumaker, S. A., Legault, C., Rapp, S. R., Thal, L., Wallace, R. B., Ockene, J. K., Hendrix, S. L., Jones III, B. N., Assaf, A. R., Jackson, R. D., et al. (2003) · JAMA · doi:10.1001/jama.289.20.2651 · Cited by 2,178
Systematic meta-analyses of Alzheimer disease genetic association studies: the AlzGene database
Bertram, L., McQueen, M. B., Mullin, K., Blacker, D., & Tanzi, R. E. (2007) · Nature Genetics · doi:10.1038/ng1934 · Cited by 1,857 · cited 1×
“Consistent with published literature [45], the most common APOE allele was ε3 among 568 women genotyped, representing 78.”
ResultStroop Color and Word Test: Manual for Clinical and Experimental Uses.
Golden, C. J., Golden, C. J., & Golden, C. (1978) · NSUWorks (Nova Southeastern University) · Cited by 1,814
Cited by
Sex differences in Alzheimer disease — the gateway to precision medicine
for the Women’s Brain Project and the Alzheimer Precision Medicine Initiative, Ferretti, M. T., Iulita, M. F., Cavedo, E., Chiesa, P. A., Schumacher Dimech, A., Santuccione Chadha, A., Baracchi, F., Girouard, H., Misoch, S., et al. (2018) · Nature Reviews Neurology · doi:10.1038/s41582-018-0032-9 · Cited by 1,009
The 2017 hormone therapy position statement of The North American Menopause Society
(2017) · Menopause · doi:10.1097/gme.0000000000000921 · Cited by 1,001
The 2022 hormone therapy position statement of The North American Menopause Society
(2022) · Menopause · doi:10.1097/gme.0000000000002028 · Cited by 977
“There is some evidence that ETenhances mood and improves well-being in nondepressed postmenopausal women.(205) Initial”
Self-citation2016 IMS Recommendations on women’s midlife health and menopause hormone therapy
Baber, R. J., Panay, N., & Fenton, A. (2016) · Climacteric · doi:10.3109/13697137.2015.1129166 · Cited by 964
Understanding the impact of sex and gender in Alzheimer’s disease: A call to action
Nebel, R. A., Aggarwal, N. T., Barnes, L. L., Gallagher, A., Goldstein, J. M., Kantarci, K., Mallampalli, M. P., Mormino, E. C., Scott, L., Yu, W. H., et al. (2018) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2018.04.008 · Cited by 839
“[80] Gleason CE, Dowling NM, Wharton W, Manson JE, Miller VM, Atwood CS, et al.”
The Menopause Transition: Signs, Symptoms, and Management Options
Santoro, N., Roeca, C., Peters, B. A., & Neal-Perry, G. (2021) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgaa764 · Cited by 631
Self-citationLong term hormone therapy for perimenopausal and postmenopausal women
Farquhar, C., Marjoribanks, J., Lethaby, A., Suckling, J. A., & Lamberts, Q. (2005) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd004143.pub2 · Cited by 582
Long-term hormone therapy for perimenopausal and postmenopausal women
Marjoribanks, J., Farquhar, C., Roberts, H., Lethaby, A., & Lee, J. (2017) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd004143.pub5 · Cited by 424
Sex and the development of Alzheimer's disease
Pike, C. J. (2017) · Journal of Neuroscience Research · doi:10.1002/jnr.23827 · Cited by 402
Dementia in Down syndrome: unique insights for Alzheimer disease research
Lott, I. T., & Head, E. (2019) · Nature Reviews Neurology · doi:10.1038/s41582-018-0132-6 · Cited by 383
Management of Menopausal Symptoms: A Review
Crandall, C. J., Mehta, J. M., & Manson, J. E. (2023) · JAMA · doi:10.1001/jama.2022.24140 · Cited by 316
Self-citationSnyder, H. M., Asthana, S., Bain, L., Brinton, R., Craft, S., Dubal, D. B., Espeland, M. A., Gatz, M., Mielke, M. M., Raber, J., et al. (2016) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2016.08.004 · Cited by 262
Self-citationGordon, J. L., Rubinow, D. R., Eisenlohr-Moul, T. A., Xia, K., Schmidt, P. J., & Girdler, S. S. (2018) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2017.3998 · Cited by 260
Hormonal Treatments for Major Depressive Disorder: State of the Art
Dwyer, J. B., Aftab, A., Radhakrishnan, R., Widge, A., Rodriguez, C. I., Carpenter, L. L., Nemeroff, C. B., McDonald, W. M., Kalin, N. H., & APA Council of Research Task Force on Novel Biomarkers and Treatments (2020) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2020.19080848 · Cited by 252
Mielke, M. M., Aggarwal, N. T., Vila‐Castelar, C., Agarwal, P., Arenaza‐Urquijo, E. M., Brett, B., Brugulat‐Serrat, A., DuBose, L. E., Eikelboom, W. S., Flatt, J., et al. (2022) · Alzheimer's & Dementia · doi:10.1002/alz.12662 · Cited by 198
Hamoda, H., Panay, N., Pedder, H., Arya, R., & Savvas, M. (2020) · Post Reproductive Health · doi:10.1177/2053369120957514 · Cited by 192
Anxiety Disorders Among Women: A Female Lifespan Approach
Hantsoo, L., & Epperson, C. N. (2017) · Focus · doi:10.1176/appi.focus.20160042 · Cited by 183
Hormone Therapy in Menopause: Concepts, Controversies, and Approach to Treatment
Flores, V. A., Pal, L., & Manson, J. E. (2021) · Endocrine Reviews · doi:10.1210/endrev/bnab011 · Cited by 174
Self-citationSex Differences in Alzheimer’s Disease: Insights From the Multiomics Landscape
Guo, L., Zhong, M. B., Zhang, L., Zhang, B., & Cai, D. (2022) · Biological Psychiatry · doi:10.1016/j.biopsych.2021.02.968 · Cited by 164
Gurvich, C., Hoy, K., Thomas, N., & Kulkarni, J. (2018) · Brain Sciences · doi:10.3390/brainsci8090163 · Cited by 150
Estrogen Receptors Modulation of Anxiety-Like Behavior
Borrow, A. P., & Handa, R. J. (2017) · Vitamins and Hormones · doi:10.1016/bs.vh.2016.08.004 · Cited by 146
“For example, in postmenopausal women, anxiety levels have been reported to either decrease (Gleason et al., 2015) or remain unaffected (Demetrio et al., 2011) following estrogen therapy.”
BackgroundColey, N., Giulioli, C., Aisen, P. S., Vellas, B., & Andrieu, S. (2022) · Ageing Research Reviews · doi:10.1016/j.arr.2022.101777 · Cited by 62
Huang, X., Wang, Y., & Zhang, H. (2023) · Asian Journal of Sport and Exercise Psychology · doi:10.1016/j.ajsep.2023.01.001 · Cited by 51
Metadata
- Authors
- Gleason, C. E., Dowling, N. M., Wharton, W., Manson, J. E., Miller, V. M., Atwood, C. S., Brinton, E. A., Cedars, M. I., Lobo, R. A., Merriam, G. R., Neal-Perry, G., Santoro, N. F., Taylor, H. S., Black, D. M., Budoff, M. J., Hodis, H. N., Naftolin, F., Harman, S. M., & Asthana, S.
- Venue
- PLOS Medicine
- Publisher
- Public Library of Science (PLoS)
- Published
- 2015-06-02
- Volume
- 12
- Issue
- 6
- Pages
- e1001833
- ISSN
- 1549-1277 (ISSN-L)
- 1549-1676
- OpenAlex
- W578040726
- Cited by
- 490
- References
- 74
- FWCI
- 38.98
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.